{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:37Z","timestamp":1787222737839,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12253-017-0324-1","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T17:30:49Z","timestamp":1506706249000},"page":"45-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-1547","authenticated-orcid":false,"given":"Kata","family":"Czirbesz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Gorka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Balatoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitta","family":"P\u00e1ncz\u00e9l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Melegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"G\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Liszkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"324_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65:5\u201329. \n                    https:\/\/doi.org\/10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"324_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998\u20131012","journal-title":"N Engl J Med"},{"issue":"8","key":"324_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723 Erratum in: N Engl J Med. 363(13):1290","journal-title":"N Engl J Med"},{"key":"324_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516","journal-title":"N Engl J Med"},{"issue":"3","key":"324_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15(3):323\u2013332","journal-title":"Lancet Oncol"},{"key":"324_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"324_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"9839","author":"A Hauschild","year":"2012","unstructured":"Hauschild A et al (2012) Dabrafenib in BRAF-mutated metastatuc melanoma:a multicentre, open-label, phase 3 randomized controlled trial. Lancet 9839:358\u2013365","journal-title":"Lancet"},{"key":"324_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA et al (2010) Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 363:809\u2013819","journal-title":"N Engl J Med"},{"key":"324_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kevin MD et al (2012) Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib. N Engl J Med 366:707\u2013714","journal-title":"N Engl J Med"},{"key":"324_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","volume":"97","author":"K Asi\u0107","year":"2016","unstructured":"Asi\u0107 K (2016) Dominant mechanisms of primary resistance differ from dominat mechanisms of secondary resistance to target therapies. Crit Rev Oncol Hematol 97:178\u2013196","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"324_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","volume":"31","author":"K Trunzer","year":"2013","unstructured":"Trunzer K, Pavlick AC, Sosman JA, Ribas A et al (2013) Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31(14):1767\u20131774","journal-title":"J Clin Oncol"},{"key":"324_CR12","doi-asserted-by":"publisher","unstructured":"Rinderknecht JD, Goldinger SM et al (2013) RASopathic Skin Eruptions during Vemurafenib Therapy. PlosOne 8(10) \n                    https:\/\/doi.org\/10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be\n                    \n                  . 2013 March 14","DOI":"10.1371\/annotation\/d884b668-04f7-4ae6-96a3-a199df5b43be"},{"issue":"3","key":"324_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","volume":"148","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Livingstone E, Hillen U, Domkes S, Becker A et al (2012) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148(3):357\u2013361","journal-title":"Arch Dermatol"},{"issue":"12","key":"324_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/atm.2016.06.07","volume":"4","author":"L Manzano Jose","year":"2016","unstructured":"Manzano Jose L, Layos L et al (2016) Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med 4(12):237","journal-title":"Ann Transl Med"},{"key":"324_CR15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dreno B et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867\u20131876","journal-title":"N Engl J Med"},{"key":"324_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248\u20131260","journal-title":"Lancet Oncol"},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"G Long","year":"2015","unstructured":"Long G et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val 600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised, controlled trial. Lancet 386:444\u2013451","journal-title":"Lancet"},{"key":"324_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma combined dabrafenib and trametinib. N Engl J Med 372:30\u201339","journal-title":"N Engl J Med"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-017-0324-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T01:28:09Z","timestamp":1567733289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-017-0324-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s12253-017-0324-1","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"assertion":[{"value":"1 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}